Evidence map›Paper›PMID 32586743›Full record

Observational studyOphthalmology2020

Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area: MacTel Project Report Number 8.

Tjebo F C Heeren, Emily Y Chew, Traci Clemons, Marcus Fruttiger, Konstantinos Balaskas, Roy Schwartz, Catherine A Egan, Peter Charbel Issa, MacTel Study Group

Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Functional Relevance of Hyper-Reflectivity in Macular Telangiectasia Type 2.Investigative ophthalmology & visual science · 2021
    Trial
  4. Review
  5. Article
  6. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  7. Article
  8. Observational
  9. Article
  10. Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Quantification of vascular changes in macular telangiectasia type 2 with AngioTool software.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Tjebo F C HeerenMoorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; UCL Institute of Ophthalmology, University College London, London, United Kingdom.
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Traci ClemonsThe Emmes Corporation, Rockville, Maryland.
Marcus FruttigerUCL Institute of Ophthalmology, University College London, London, United Kingdom.
Konstantinos BalaskasMoorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Roy SchwartzMoorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Catherine A EganMoorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
Peter Charbel IssaOxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, and Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom. Electronic address: study-enquiry@outlook.com.
MacTel Study Group
Moorfields Eye Hospital NHS Foundation Trust · GBEmmes (United States) · USNational Institutes of Health · USUniversity College London · GBUniversity of Oxford · GB

Funding

Phase 2 Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel) (14-EI-0078, 17-EI-0136)ZIAEY000536 · NEI · NATIONAL EYE INSTITUTE · PI CHEW, EMILY Y · 2014 to 2025
$635k
MACTEL2ZIAEY000493 · NEI · NATIONAL EYE INSTITUTE · PI CHEW, EMILY Y · 2010 to 2013
$72k
Intramural NIH HHS ZIA EY000493
6 · The paper itself

Abstract

purposeTo report the visual acuity measures from the macular telangiectasia type 2 (MacTel) registry and to investigate and describe phenotypic findings in eyes with substantial vision loss resulting from MacTel.

designCross-sectional multicenter study.

participantsParticipants in the MacTel Natural History Observation Registration Study.

methodsBest-corrected visual acuity (BCVA) data, retinal imaging data, and clinical data were accessed from the MacTel Study databases in May 2019.

main outcome measuresFrequency distribution of BCVA and its relationship to age; morphologic changes in eyes with very late disease stages, defined by a BCVA of 20/200 or worse; average retinal thickness of macular subfields on OCT; and dimensions of the area affected by MacTel (i.e., the MacTel area).

resultsBest-corrected visual acuity was 20/50 or worse in 37.3% and 20/200 or worse in 3.8% of 4449 eyes of 2248 patients; 18.4% and 0.7% of all patients showed bilateral BCVA of 20/50 or worse and 20/200 or worse, respectively. Asymmetry between right and left eyes was present (median BCVA, 71 letters vs. 74 letters), a finding supported by more advanced morphologic changes in right eyes. Participant age correlated with BCVA, but the effect size was small. If a neovascularization or macular hole were present, bilateral occurrence was frequent (33% or 17%, respectively), and BCVA was better than 20/200 (79% or 78%, respectively) or 20/50 or better (26% or 13%, respectively). Eyes with advanced disease (BCVA, ≤20/200) showed the following characteristics: (1) atrophy of the foveal photoreceptor layer with or without associated subretinal fibrosis; (2) an affected area, termed MacTel area, limited to a horizontal diameter not exceeding the distance between the temporal optic disc margin and foveal center, and the vertical diameter not exceeding approximately 0.8 times this distance (exceptions were eyes with large active or inactive neovascular membranes); (3) reduced retinal thickness measures within the MacTel area; and (4) less frequent retinal greying and more frequent hyperpigmentations compared with eyes that have better BCVA.

conclusionsSevere vision loss is rare in MacTel and is related to photoreceptor atrophy in most people. Results indicate disease asymmetry with slightly worse vision and more advanced disease manifestation in right eyes. MacTel-related neurodegeneration does not spread beyond the limits of the MacTel area.

Indexed as

Visual AcuityAdultAgedAged, 80 and overCross-Sectional StudiesFemaleFluorescein AngiographyFovea CentralisFundus OculiHumansMaleMiddle AgedRetinal TelangiectasisRetrospective StudiesYoung Adult

Identifiers

PMID32586743
PMCPMC8380038
OpenAlexW3019081745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.